A Phase II Study of continuous, low-dose LBH 589 (Panobinostat) in Patients with Refractory Solid Tumors, including CNS tumors

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1129147

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Research done recently across three separate Australian laboratories has shown great promise with a new anti-cancer drug LBH589 used for cancers in children and young adults. We wish to start a clinical trial of LBH589 in children and young adult patients with cancer.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2021

Funding Scheme: Project Grants

Funding Amount: $811,512.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer therapy | epigenetics | histone deacetylase | neuroblastoma | sarcoma

Related Links